SDB Investment is donating KRW 25 billion(₩) to Seoul National University. Seoul National University held a signing ceremony for Bionote, Inc., in the presence of key figures from the school including President Se-Jeong Oh, Vice President of Planning Won-Woo Lee, Dean of Veterinary Medicine Ho-Jae Han, and many others. A plaque of appreciation has also been delivered to SD Biosensor/Bionote Chairman Cho Young-Sik. After graduating from Seoul National University's College of Veterinary Medicine in 1984, Cho joined Green Cross, a pharmaceutical company. There, he was in charge of developing diagnostic reagent and product production for 13 years, and also served as a manager for domestic and overseas marketing division. During his career, he graduated from Seoul National University College of Veterinary Medicine with Master's and Doctorate degrees in veterinary biochemistry to further improve his professional capabilities. As the current chairman of SD Biosensor, Inc., and the CEO of SDB Investment, Cho has successfully founded SD Biosensor and Bionote to be a global diagnostic company for the human and veterinary field each. "For the past 2 years, humanity has suffered the unforeseen pandemic. Such illness can easily be eradicated with the cutting-edge technology utilizing A.I. (Artificial Intelligence)," said Cho. "Korea needs to actively support on the A.I. program to help flourish the bio industry." "I hope the contribution made today can be the stepping stone for the Korea's biotechnology industry." said Cho. Among the ₩25 billion donation, ₩20 billion will be dedicated to ‘Data Center Research Fund’ to build a GPU-based data center and support convergence research. Remaining ₩5 billion will be dedicated to the ‘Education and Research Environment Improvement Project Fund of the College of Veterinary Medicine’. Seoul National University has claimed that the donation will be cherished to support excellent researchers to induce innovation and growth.
The Korean Veterinary Association held 2nd National Veterinary Advisory Council (NVAC) at Bionote, Inc., on April 26th, 2022. The NVAC is an official advisory body within the Veterinary Society, providing advice to the government on the prevention of malignant livestock diseases such as FMD, ASF and major zoonotic diseases, while also serving to establish an official veterinary medical system. Key figures at NVAC 2022 includes: Chairman Yong-Ho Park (Seoul National University Veterinary College), ▲ Jong-Gu Kang (Biotoxtech), ▲ Jong-Kil Kang (Chunghyeon General Veterinary Hospital), ▲ Gon-Seop Kim (Gyeongsang National University Veterinary College), ▲ Woo-Joo Kim (Korea University Guro Hospital), ▲ Young-Soo Ryu (Konkuk University Veterinary College) , ▲Seungwon Seo (Boehringer Ingelheim Veterinary Medicine), ▲Sangcheol Shin (Solgent), ▲Chunggeun Yoon (Asia Veterinary Hospital), ▲Soodu Lee (Ministry of Food and Drug Safety), ▲Poongkyu Lee (Knowhere bio), ▲Youngsik Cho (Bionote). For this year's council meeting, Professor Kim Woo-Joo, Department of Infectious Diseases at the Korea University Guro Hospital, discussed the current status of the COVID-19 pandemic, development of vaccines, changes due to the emergence of mutants, and future prospects and countermeasures, under the theme of 'COVID-19 Pandemic: Current Status and Prospects'. Bionote is the No. 1 manufacturer for veterinary diagnostic reagents in Korea. For its post pandemic growth engine, Bionote will be focusing on expanding its business sector via molecular diagnostic analyzer Vcheck M, biochemistry analyzer Vcheck C, and bio-contents business.
A paper on the analytical validation of Vcheck Canine NT-proBNP (BIONOTE) has been published in the international journal, Veterinary Clinical Pathology (Science Citation Index, Impact factor 1.18).Paper: Analytical validation of a novel point-of-care immunoassay for canine N-terminal pro-brain natriuretic peptide analysis (Vet Clin Pathol. 2022;00:1–10.) See the attached document for the summary and click here for the full paper (open access). This study aimed to analytically validate a Vcheck NT-proBNP assay according to American Society of Veterinary Clinical Pathology (ASVCP) and Clinical Laboratory Improvement Amendments (CLIA) specifications. Precision Imprecision was considered acceptable with a coefficient of variation ranging from 9% at 4000 pmol/L to 20% at 600 pmol/L. Accuracy Comparison of the Vcheck assay with the Cardiopet NT-proBNP assay revealed an excellent correlation with minimal bias (y=0.9x+37, R2=0.9) when preanalytical factors were controlled. Preanalytical error Significant degradation of NT-proBNP occurred when current methods were used at refrigerated (average loss of 20%) and room temperatures (loss of at least 50%), which could change diagnostic and prognostic decision-making. Interferents (analytical specificity) Spiking samples across the linear range of the assay with 35 mg/dL hemoglobin and 1000 mg/dL Intralipid did not reveal a statistically significant difference. Reference intervals Age-partitioned reference intervals (95%) have upper reference limits of 750 pmol/L and 1280 pmol/L for 36 juvenile and 125 adult dogs, respectively. According to this study, the Vcheck assay provides analytically acceptable results. Onsite testing can minimize variability related to preanalytical error and provide clinically useful contemporaneous results. Also, the author emphasized that samples should be centrifuged immediately and analyzed within 2 hours of collection, due to significant degradation of NT-proBNP. Results of this study demonstrate that the Vcheck NT-proBNP assay is a valid point-of-care cardiac biomarker using the canine serum. Vcheck Canine NT-proBNP can be quantitatively measured using a fluorescent immunoassay analyzer (Vcheck) in a short time (15 minutes) and can be tested using a small amount of sample (serum 100 µl). Learn more